Photodynamic therapy composition

Patent metadata

Field	Value
Publication number	US-12521435-B2
Application number	US-202117368574-A
Country	US
Kind code	B2
Filing date	Jul 6, 2021
Priority date	Jul 3, 2020
Publication date	Jan 13, 2026
Grant date	Jan 13, 2026

Abstract

A photodynamic therapy composition, the composition includes a plurality of targeted phthalocyanine gold nanoparticle conjugates, wherein each targeted phthalocyanine gold nanoparticle conjugate includes a plurality of phthalocyanine compounds covalently coupled to a surface of the gold nanoparticle via bio-cleavable linker and a plurality of cancer or tissue targeting agents coupled to the gold nanoparticle.

First claim

Having described the invention, I claim:

1 . A photodynamic therapy composition comprising:
a plurality of targeted phthalocyanine gold nanoparticle conjugates, wherein each targeted phthalocyanine gold nanoparticle conjugate includes a plurality of phthalocyanine compounds covalently coupled directly to a surface of a gold nanoparticle via bio-cleavable linkers and a plurality of cancer or tissue targeting agents coupled to the gold nanoparticle, wherein the bio-cleavable linker is a lysosomal cleavable peptide having the amino acid sequence GFLGC (SEQ ID NO:1), and wherein the surface of the gold nanoparticle is directly conjugated to the cysteine residue of the bio-cleavable linker via an Au—S bond.

2 . The photodynamic therapy composition of claim 1 , wherein the phthalocyanine compound prior to covalent coupling to the surface of the gold nanoparticle has the formula (I):

wherein m is 1-5;
R 1 , R 4 , R 5 , R 8 , R 9 , R 12 , R 13 , and R 16 are each independently selected from the group consisting of hydrogen, halogen, nitro, cyano, hydroxyl, thiol, amino, and methyl;
R 2 , R 3 , R 6 , R 7 , R 10 , R 11 , R 14 , and R 15 are each independently selected from the group consisting of hydrogen, halogen, nitro, cyano, hydroxyl, thiol, amino, carboxy, aryl, heteroaryl, carbocyclyl, heterocyclyl, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, C 1-6 alkoxy, C 1-6 acyl, C 1-6 alkylcarbonyloxy, C 1-6 carbocyclylalkyl, C 1-6 aminoalkyl, C 1-6 alkylamino, C 1-6 thioalkyl, C 1-6 alkylthio, C 1-6 hydroxyalkyl, C 1-6 alkyloxycarbonyl, C 1-6 alkylaminocarbonyl, and C 1-6 alkylcarbonylamino; and pharmaceutically acceptable salts thereof.

3 . The photodynamic therapy composition of claim 2 , wherein R 1 -R 16 of the phthalocyanine compound are independently selected from the group consisting of hydrogen, halogen, nitro, cyano, hydroxyl, thiol, amino, and methyl.

4 . The photodynamic therapy composition of claim 2 , wherein the phthalocyanine compound has the formula (IV):

and pharmaceutically acceptable salts thereof.

5 . The photodynamic therapy composition of claim 1 , wherein the gold nanoparticle is PEGylated and the plurality of cancer or tissue targeting agents coupled to the gold nanoparticle include at least one PSMA ligand coupled to polyethylene glycol of the gold nanoparticle for targeting the composition to a PSMA expressing cancer cell.

6 . A method for treating a PSMA expressing cancer in a subject in need thereof, the method comprising:
(a) administering systemically to the subject therapeutically effective amount of a photodynamic therapy composition, the photodynamic therapy composition including a plurality of targeted phthalocyanine gold nanoparticle conjugates, wherein each targeted phthalocyanine gold nanoparticle conjugate includes a plurality of phthalocyanine compounds covalently coupled directly to a surface of a gold nanoparticle via bio-cleavable linker and a plurality of PSMA ligands coupled to the gold nanoparticle, wherein the bio-cleavable linker is a lysosomal cleavable peptide having the amino acid sequence GFLGC (SEQ ID NO:1), and wherein the surface of the gold nanoparticle is directly conjugated to the cysteine residue of the bio-cleavable linker via an Au—S bond; and (b) exposing the phthalocyanine compounds to near infrared (NIR) light, thereby inducing the cytotoxic effects of the phthalocyanine compound.

7 . The method of claim 6 , wherein the phthalocyanine compounds are exposed to NIR light after being enzymatically cleaved from the targeted phthalocyanine gold nanoparticle conjugates in an endolysosomal vesicle of a targeted cancer cell, and wherein the conjugated phthalocyanine compounds are inactive prior to cleavage from the targeted gold nanoparticle.

8 . The method of claim 6 , wherein the photodynamic therapy composition is administered by intravenous injection.

9 . The method of claim 6 , wherein the PSMA expressing cancer is selected from the group consisting of renal carcinoma, transitional cell carcinoma of the urinary bladder, testicular embryonal carcinoma, colonic adenocarcinoma, neuroendocrine carcinoma, gliobastoma multiforme, malignant melanoma, pancreatic ductal carcinoma, non-small cell lung carcinoma, soft tissue carcinoma, breast carcinoma, and prostatic adenocarcinoma.

10 . The method of claim 6 , wherein the PSMA expressing cancer is metastatic prostate cancer.

11 . The method of claim 6 , wherein the step of exposing at least one of the plurality of phthalocyanine compounds to near infrared (NIR) light includes administering to the subject at least one therapeutically effective amount of NIR light following administration of the photodynamic therapy composition to the subject.

12 . The method of claim 10 , wherein NIR light is administered between about 6 to about 24 hours after the photodynamic therapy composition is administered to the subject.

13 . The method of claim 11 , wherein NIR light is sequentially administered at least three times following administration of the photodynamic therapy composition to the subject, and wherein each NIR administration results in increased photodynamic therapy composition accumulation in the subject's cancer cells.

14 . The method of claim 12 , wherein NIR light is first administered between about 6 to about 24 hours after the photodynamic therapy composition is administered to the subject, and one or more subsequent NIR light administrations are administered to the subject about 24 hours after the previous administration.

15 . A method for treating a PSMA expressing cancer comprising:
(a) administering systemically to the subject therapeutically effective amount of a photodynamic therapy composition, the photodynamic therapy composition including a plurality of targeted phthalocyanine gold nanoparticle conjugates, wherein each targeted phthalocyanine gold nanoparticle conjugate includes a plurality of phthalocyanine compounds covalently coupled directly to a surface of a gold nanoparticle via bio-cleavable linker and a plurality of PSMA ligands coupled to the gold nanoparticle, wherein the bio-cleavable linker is a lysosomal cleavable peptide having the amino acid sequence GFLGC (SEQ ID NO:1), and wherein the surface of the gold nanoparticle is directly conjugated to the cysteine residue of the bio-cleavable linker via an Au—S bond; and (b) exposing the phthalocyanine compound to near infrared (NIR) light, thereby inducing the cytotoxic effects of the phthalocyanine compound, wherein NIR light is sequentially administered at least three times following administration of the photodynamic therapy composition to the subject, and wherein each NIR administration results in increased photodynamic therapy composition accumulation in the subject's cancer cells.

16 . The method of claim 15 , wherein NIR light is first administered between about 6 to about 24 hours after the photodynamic therapy composition is administered to the subject, and each subsequent NIR light administration is about 24 hours after the previous administration.

17 . The method of claim 15 , wherein the phthalocyanine compounds are exposed to NIR light after being enzymatically cleaved from the targeted phthalocyanine gold nanoparticle conjugates in an endolysosomal vesicle of a targeted cancer cell, and wherein the conjugated phthalocyanine compounds a

Assignees

• Univ Case Western Reserve

Inventors

• Basilion James

Classifications

• A61K47/6929

  the form being a nanoparticle, e.g. an immuno-nanoparticle · CPC title

• A61K47/60

  the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol · CPC title

• B82Y5/00

  Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery · CPC title

• A61K47/65

  Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers · CPC title

• A61K47/6923

  the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb · CPC title